Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. - Test2 - elhamkhani - TriplyDB

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.

http://www.wikidata.org/entity/Q34036950

about

Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD Current Management of NAFLD Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment Residual macrovascular risk in 2013: what have we learned?Nonalcoholic fatty liver disease: new treatments The impact of PPARα activation on whole genome gene expression in human precision cut liver slices PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Evolving targets for lipid-modifying therapy Exercise training improves liver steatosis in mice PPARs and Mitochondrial Metabolism: From NAFLD to HCC.Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions.Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.Pharmacological agents for NASH.Evolving therapies for non-alcoholic steatohepatitis.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Nonalcoholic fatty liver disease - current status and future directions.Review article: new treatments in non-alcoholic fatty liver disease.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp.Treatment options for nonalcoholic steatohepatitis - a safety evaluation.Current and future pharmacologic treatment of nonalcoholic steatohepatitis.Management of NAFLD: a stage-based approach.Current and future treatment options in non-alcoholic steatohepatitis (NASH).The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.The role of macrophages in obesity-driven chronic liver disease.Nuclear receptors and nonalcoholic fatty liver disease.Therapies in non-alcoholic steatohepatitis (NASH).Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.

P2860

Q24563381-95D2AF3B-B5DD-4ED1-B9D5-728B507BB5B6 Q26745533-0A4074B5-FBEE-454F-A46A-81D67278CB25 Q26747009-BCDF686E-5F68-44F2-9D66-7960CEB9EB5B Q26751258-4D526AA3-5FDD-4394-9F24-19F9DEDF9A9D Q26752487-C40C77F6-7B87-4024-9582-CE8863EE5A72 Q26752729-18AA4160-8A2C-48AF-992D-30F59072A628 Q26830274-032F158A-C3D4-45BF-8DA8-4BF45AA5AA60 Q26852019-42B6B663-D2AA-4A75-9586-00E37E30DEC7 Q26996039-EF827C1B-DE0F-46AF-B825-5D1573EFC012 Q27021161-95D28D6A-EF11-4B45-9829-A3AED3471115 Q28606579-A99A8C0D-11A8-41BE-AF0A-24E1F021006E Q30241952-045098BD-7008-457D-BFF3-D9830EA27316 Q34041838-30987B88-BD46-49CB-8C8B-DB6A89B6E7DB Q34041987-592DC505-962C-49A5-B400-B3FC9175AB63 Q34398065-F7B740EF-DBA5-4D12-8311-59AB85EB0E87 Q34422821-6B88DA28-F77F-4EF9-9E91-DF8C61D06E49 Q34540703-3215A8E5-B4ED-41B8-89ED-2ED695098E11 Q34880292-95C25E97-2425-4D1D-A1A5-B39A9FD68D79 Q35923163-8D65925D-3687-4BF4-A08A-001F7E7D0B5D Q37575571-9FF8289A-F876-49A9-BCA1-E11D76A94A32 Q37578702-6A612C2F-3F4B-4067-8F17-A062745FBB07 Q37662933-59BEA8C0-AA0C-46E2-B724-4222E59559BB Q38152646-05F6CC95-213B-4E6D-AE48-C3F1A297EDC4 Q38207111-9466926D-C11E-4A40-AF11-06258084F5E1 Q38325814-B5ED8AE8-CC0F-4D90-BE73-8B48253A5F02 Q38580461-F9AB830F-4480-4512-8AC9-951E851B18B2 Q38592767-F7A0AB04-D571-48E3-9960-20DF570C7A4E Q38662765-E0E14E03-32D7-4398-8EF6-DF6EA89C3ACB Q38674739-D5C9FCF3-6D80-42DB-A60F-8D5DDBC2BE8A Q38674742-3602E726-B476-4FF9-A673-441D55222EB6 Q38691457-D215C626-FC4E-4972-AC5C-802857150B5A Q38713765-56679BF7-DE4F-4EDB-9D84-97BE436F2869 Q38739205-BEB86152-3277-4FEF-9C83-6515418375D1 Q38747405-F065A93C-ACBA-4585-8E8B-5B7F73AD9648 Q38748381-3B39B88B-E07C-46D3-A8BD-E3BB437F918D Q38752520-EFFE4B99-34B1-4E33-B6BE-D2A9E5BC5D08 Q38758810-D8FB5000-833A-475C-A3D2-9222E1233A7D Q38768048-9CAF9EF5-9BD7-4A90-B303-2726C1FEDD1A Q38774861-3B1F8C16-2B6A-4FEF-854D-446B7AFCD4DF Q38778064-49E1C886-73ED-421A-927B-F7A8D2EC77A9

P2860

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.

http://www.wikidata.org/entity/Q34036950

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Dual peroxisome proliferator-a ...... in abdominally obese subjects.

@ast

Dual peroxisome proliferator-a ...... in abdominally obese subjects.

@en

Dual peroxisome proliferator-a ...... in abdominally obese subjects.

@nl

type

label

Dual peroxisome proliferator-a ...... in abdominally obese subjects.

@ast

Dual peroxisome proliferator-a ...... in abdominally obese subjects.

@en

Dual peroxisome proliferator-a ...... in abdominally obese subjects.

@nl

prefLabel

Dual peroxisome proliferator-a ...... in abdominally obese subjects.

@ast

Dual peroxisome proliferator-a ...... in abdominally obese subjects.

@en

Dual peroxisome proliferator-a ...... in abdominally obese subjects.

@nl

P1433

Q34036950-DBADFF62-D8E1-4C7E-A84F-A72461B99F89

P1476

Q34036950-3C967991-F475-46AE-9827-35E01B8331F1

P2093

Q34036950-280769D7-490C-41CE-979F-14DDE2EE659D

Q34036950-43513788-ED56-4593-83F4-45FE43156FE6

Q34036950-62700120-6B90-46EC-B7C7-344EBD309B02

Q34036950-900AD673-81AA-43E9-94D7-F679190743B9

Q34036950-9AE0639F-67D3-452C-A617-9388D7E3A7A8

Q34036950-E19EEAB9-4A86-443C-A6E3-6BA02E6425BD

Q34036950-F240119A-8596-402D-992B-38552470FDB7

P2860

Q34036950-07CA4115-D17F-42DF-8F5B-B8CFA22E036C

Q34036950-15A48955-5620-41A4-B7A3-48745399257D

Q34036950-31FDE38F-4043-4115-8ECD-79DE017108C2

Q34036950-374501A0-5E3A-48AC-A913-B9AF974054DA

Q34036950-38431CA8-401D-4AD5-BCB5-73DEB868D06D

Q34036950-3DDDAFE7-FDBC-42C0-8253-6D76657BE2B2

Q34036950-4C9A5F75-8CE1-4354-B1B8-606FD2C21230

Q34036950-541BB9EB-92E6-4609-B28B-5EB955886660

Q34036950-58D9103E-56CE-4CB4-85EE-6FBE0C30AC59

Q34036950-66BCF6B5-C624-4E63-BDF2-403EE31A2299

P304

Q34036950-E317A81D-FC80-424A-8E68-4BF00FFD7025

P31

Q34036950-80F4CFCD-42A9-452B-AC24-8A5825403B6E

P356

Q34036950-4135A543-E0A3-47CD-A394-687C4A69430A

P407

Q34036950-CB87A618-894D-4359-B097-2D5F3B959E19

P433

Q34036950-D054BC6C-BD3C-45A8-9477-4DD80AD15CDA

P478

Q34036950-77D23F6A-02D6-4303-AF32-F27D20172C94

P50

Q34036950-3AD10278-42A5-4D60-B978-891737AE4D76

Q34036950-7300D221-D282-43E0-AA6A-1004D97210D3

Q34036950-D47A0282-6CA8-4F12-BCEE-C3250C860C6F

P577

Q34036950-1C503279-EBA9-42AD-85BB-CD2F57534D07

P5875

Q34036950-FC543951-C839-480A-B580-5B5BEB7A51E6

P698

Q34036950-68029579-BCFE-4D35-945E-A2425302AB77

P921

Q34036950-2EE888B5-A7BF-4598-8951-82CABCF1D735

Q34036950-AF9B0FCE-E731-4618-948A-B789A8C91E3D

P932

Q34036950-C4CFA564-FD37-4CB9-9807-CA3307B5DFAF

P356

P1433

P1476

Dual peroxisome proliferator-a ...... in abdominally obese subjects.

@en

P2093

Benoit Noël

http://www.w3.org/2001/XMLSchema#string

Bertrand Cariou

http://www.w3.org/2001/XMLSchema#string

Martine Laville

http://www.w3.org/2001/XMLSchema#string

Rémy Hanf

http://www.w3.org/2001/XMLSchema#string

Stéphanie Lambert-Porcheron

http://www.w3.org/2001/XMLSchema#string

Valérie Sauvinet

http://www.w3.org/2001/XMLSchema#string

Yassine Zaïr

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Insulin signalling and the regulation of glucose and lipid metabolism

Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta

PPARdelta regulates glucose metabolism and insulin sensitivity

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome

Cellular mechanisms of insulin resistance

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

Effects of combination lipid therapy in type 2 diabetes mellitus.

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

P304

2923-2930

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC12-2012

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236957950

http://www.w3.org/2001/XMLSchema#string

P698

23715754

http://www.w3.org/2001/XMLSchema#string

P921

P932

3781493

http://www.w3.org/2001/XMLSchema#string